• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fresenius Medical Care AG

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    SC 13G 1 formsc13g-11142024_091150.htm FORM schedule-13g


     
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934


     
    Fresenius Medical Care AG
    (Name of Issuer)
    Ordinary Shares, no par value €1.00
    (Title of Class of Securities)
    358029106
    (CUSIP Number)
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ x ] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [   ] Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     


     
    CUSIP No. 358029106
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        HARRIS ASSOCIATES L P

        04-3276558

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)  
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        US

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        15,039,485

       (6)   

    Shared Voting Power

     

        0

       (7)   

    Sole Dispositive Power

     

        15,173,585

       (8)   

    Shared Dispositive Power

     

        0

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        15,173,585

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        5.17%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IA


    CUSIP No. 358029106
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Harris Associates, Inc.

        04-3276549

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)  
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        US

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        15,039,485

       (6)   

    Shared Voting Power

     

        0

       (7)   

    Sole Dispositive Power

     

        15,173,585

       (8)   

    Shared Dispositive Power

     

        0

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        15,173,585

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        5.17%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        CO


    Item 1.
    (a) Name of Issuer
    (b) Address of Issuer's Principal Executive Offices
    Else-Kroner-Strasse 1
    Bad Homburg, Germany, 2M 61352

    Item 2.
    (a) Name of Person Filing
    Harris Associates L.P. ("Harris")
    Harris Associates, Inc. ("General Partner")

    **Harris Associates, Inc., for itself and as General Partner
    (b) Address of Principal Business Office or, if none, Residence
    111 South Wacker Drive Suite 4600, Chicago, IL 60606
    (c) Citizenship
    See Item 4 on the cover page(s) hereto.
    (d) Title of Class of Securities
    Ordinary Shares, no par value €1.00
    (e) CUSIP Number
    358029106

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [   ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    [   ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [   ]
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [   ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ x ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [   ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [   ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [   ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [   ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [   ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4.
    (a) Amount beneficially owned:
    By reason of advisory and other relationships with the person who owns the Shares, Harris may be deemed to be the beneficial owner of the shares specified in Item 9 on the cover
    page(s) hereto. Harris has been granted the power to vote Shares in circumstances it determines to be appropriate in connection with assisting its advised clients to whom it renders
    financial advice in the ordinary course of business, by either providing information or advice to the persons having such power, or by exercising the power to vote.
    (b) Percent of class:
    See Item 11 on the cover page(s) hereto.
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote
    See Item 5 on the cover page(s) hereto.
    (ii) Shared power to vote or to direct the vote
    See Item 6 on the cover page(s) hereto.
    (iii) Sole power to dispose or to direct the disposition of
    See Item 7 on the cover page(s) hereto.
    (iv) Shared power to dispose or to direct the disposition of
    See Item 8 on the cover page(s) hereto.

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ]

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    N/A

    Item 8. Identification and Classification of Members of the Group.
    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).

    Item 9. Notice of Dissolution of Group.
    N/A

    Item 10. Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     


     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:   November 14, 2024
    Harris Associates L.P.
    By: /s/ Joseph J. Allessie

    Name: Joseph J. Allessie
    Title: General Counsel and Secretary


    Get the next $FMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    7/12/2023Buy
    Goldman
    More analyst ratings

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

    Total volume of the initial share buyback is up to EUR 1 billion over two yearsShare buyback to take place until August 10, 2027BAD HOMBURG, Germany, Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.

    8/11/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

    Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life SciencesProvides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registryPaves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis effo

    7/31/25 8:30:00 AM ET
    $AZTA
    $FMS
    Industrial Machinery/Components
    Technology
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    SEC Filings

    View All

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/11/25 7:34:34 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/5/25 10:19:53 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    8/5/25 6:00:31 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fresenius Medical upgraded by BofA Securities

    BofA Securities upgraded Fresenius Medical from Underperform to Neutral

    12/2/24 8:51:34 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Berenberg initiated coverage on Fresenius Medical with a new price target

    Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

    11/6/24 6:26:23 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical downgraded by Morgan Stanley

    Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight

    1/8/24 7:47:44 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Financials

    Live finance-specific insights

    View All

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

    FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

    6/17/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History

    Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro

    5/22/25 11:45:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

    SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

    2/13/24 1:36:58 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

    SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

    12/7/23 11:45:52 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    View All

    Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

    Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

    3/13/24 10:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

    BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany.   Fresenius Medical Care succ

    2/5/24 8:57:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

    Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a

    7/14/23 11:34:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care